Virchows Archiv

, Volume 446, Issue 5, pp 497–504

Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction

  • Marinke Westerterp
  • Linetta B. Koppert
  • Christianne J. Buskens
  • Hugo W. Tilanus
  • Fiebo J. W. ten Kate
  • Jacques J. H. G. M. Bergman
  • Peter D. Siersema
  • Herman van Dekken
  • Jan J. B. van Lanschot
Original Article

Abstract

Adenocarcinoma of the esophagus, or GEJ, has a poor prognosis. Early lesions [i.e. high grade dysplasia (HGD) or T1-carcinoma] are potentially curable. Local endoscopic therapies are promising treatment options for superficial lesions; however, for deeper lesions, surgical resection is considered to be the treatment of choice. To contribute to therapeutic decision-making, we retrospectively analysed the outcome of transhiatal esophagectomy in 120 patients with pathologically proven HGD (n=13) or T1-adenocarcinoma (n=107) of the distal esophagus or gastro-esophageal junction (GEJ). Tumors were subdivided into six different depths of invasion (‘T1-mucosal’ m1-m3, ‘T1-submucosal’ sm1-sm3), and the frequency of lymphatic dissemination and time to locoregional and/or distant recurrence were analysed. Only one of the 79 T1m1-3/sm1 tumors (1%) showed lymph node metastases as compared with 18 out of 41 T1sm2-3 tumors (44%). There was a significant difference in recurrence-free period between T1m1-m3/sm1 versus T1sm2-sm3 tumor patients (P log rank <0.0001), with 5-year recurrence-free percentages of 97% and 57%, respectively. In multivariate analysis including age, gender, tumor differentiation grade, N-stage and depth of invasion, only N-stage was an independent prognostic factor for recurrence-free period (hazard rate=5.9, 95% CI 1.7–20.7). However, if N-stage was excluded from analysis, only depth of invasion (T1sm2-3 versus T1m1-m3/sm1) was an independent prognostic factor for recurrence-free period (hazard rate=7.5, 95% CI 2.0–27.7). These data indicate that T1m1-m3/sm1 adenocarcinomas of esophagus or GEJ show a very low risk of lymphatic dissemination and are therefore eligible for local endoscopic therapy. After transhiatal surgical resection, almost half of the patients with T1sm2-sm3 lesions develop recurrent disease within 5 years, and therefore need additional therapy to improve survival.

Keywords

Barrett’s esophagus GEJ Early cancer Substage Survival 

References

  1. 1.
    Akiyama H, Tsurumaru M, Kawamura T, Ono Y (1981) Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg 194:438–446Google Scholar
  2. 2.
    Akiyama H, Tsurumaru M, Ono Y, Udagawa H, Kajiyama Y (1994) Esophagectomy without thoracotomy with vagal preservation. J Am Coll Surg 178:83–85Google Scholar
  3. 3.
    Bruno MJ (2003) Magnification endoscopy, high resolution endoscopy, and chromoscopy; towards a better optical diagnosis. Gut 52(Suppl 4):iv7–iv11Google Scholar
  4. 4.
    Buskens CJ, Westerterp M, Lagarde SM, Bergman JJ, ten Kate FJ, van Lanschot JJ (2004) Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 60:703–710Google Scholar
  5. 5.
    Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N (1999) Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study. Am J Gastroenterol 94:86–91Google Scholar
  6. 6.
    Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, Henrich R, Vieth M, Muller H, Seitz G, Stolte M (2000) Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology 118:670–677Google Scholar
  7. 7.
    Falk GW (2002) Barrett’s esophagus. Gastroenterology 122:1569–1591Google Scholar
  8. 8.
    Froelicher P, Miller G (1986) The European experience with esophageal cancer limited to the mucosa and submucosa. Gastrointest Endosc 32:88–90Google Scholar
  9. 9.
    Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, Ell C (1998) Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology 114:448–455Google Scholar
  10. 10.
    Hage M, Siersema PD, van Dekken H, Steyerberg EW, Haringsma J, van de Vrie W, Grool TE, van Veen RLP, Sterenborg HCJM, Kuipers EJ (2004) 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomized trial. Gut 53:785–790Google Scholar
  11. 11.
    Holscher AH, Bollschweiler E, Schneider PM, Siewert JR (1995) Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma. Cancer 76:178–186Google Scholar
  12. 12.
    Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347:1662–1669Google Scholar
  13. 13.
    Japanese Society of Esophageal Diseases (1999) Guidelines for the clinical and pathologic studies on carcinoma of the esophagus, 9th edn. Kanehara, TokyoGoogle Scholar
  14. 14.
    Kelly S, Harris KM, Berry E, Hutton J, Roderick P, Cullingworth J, Gathercole L, Smith MA (2001) A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 49:534–539Google Scholar
  15. 15.
    Lerut T, Coosemans W, van Raemdonck D, Dillemans B, De Leyn P, Marnette JM, Geboes K (1994) Surgical treatment of Barrett’s carcinoma:correlation between morphologic findings and prognosis. J Thorac Cardiovasc Surg 107:1059–1065Google Scholar
  16. 16.
    Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E (1992) Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 216:583–590Google Scholar
  17. 17.
    Medical Research Counsil Esophageal Cancer Working Group (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727–1733Google Scholar
  18. 18.
    Meining A, Dittler HJ, Wolf A, Lorenz R, Schusdziarra V, Siewert JR, Classen M, Höfler H, Rösch T (2002) You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 50:599–603Google Scholar
  19. 19.
    Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW (1992) Outcome of surgical treatment of adenocarcinoma in Barrett’s oesophagus. Gut 33:1454–1458Google Scholar
  20. 20.
    Millikan KW, Silverstein J, Hart V, Blair K, Bines S, Roberts J, Doolas A (1995) A 15-year review of esophagectomy for carcinoma of the esophagus and cardia. Arch Surg 130:617–624Google Scholar
  21. 21.
    Offerhaus GJ, Correa P, van Eeden S, Geboes K, Drillenburg P, Vieth M, van Velthuysen ML, Watanabe H, Sipponen P, ten Kate FJ, Bosman FT, Bosma A, Ristimaki A, van Dekken H, Riddell R, Tytgat GN (2003) Report of an Amsterdam working group on Barrett esophagus. Virchows Arch 443:602–608Google Scholar
  22. 22.
    Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC (1992) Barrett’s esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg 54:199–204Google Scholar
  23. 23.
    Rice TW, Blackstone EH, Goldblum JR, DeCamp MM, Murthy SC, Falk GW, Ormsby AH, Rybicki LA, Richter JE, Adelstein DJ (2001) Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 122:1077–1090Google Scholar
  24. 24.
    Riegman PHJ, Vissers KJ, Alers JC, Geelen E, Hop WCJ, Tilanus HW, van Dekken H (2001) Genomic alterations in malignant transformation of Barrett’s esophagus. Cancer Res 61:3164–3170Google Scholar
  25. 25.
    Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457–1459Google Scholar
  26. 26.
    Sobin LH, Wittekind C (2002) TNM classification of malignant tumours: International Union Against Cancer (UICC), 6th edn. Wiley-Liss, New York, pp 60–68Google Scholar
  27. 27.
    Stein HJ, Feith M, Mueller J, Werner M, Siewert JR (2000) Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg 232:733–742Google Scholar
  28. 28.
    Streitz JM Jr, Ellis FH Jr, Gibb SP, Balogh K, Watkins E Jr (1991) Adenocarcinoma in Barrett’s esophagus. A clinicopathologic study of 65 cases. Ann Surg 213:122–125Google Scholar
  29. 29.
    Takubo K, Sasajima K, Yamashita K, Tanaka Y, Fujita K (1991) Double muscularis mucosae in Barrett’s esophagus. Hum Pathol 22:1158–1161Google Scholar
  30. 30.
    Van Dam J (2003) Novel methods of enhanced endoscopic imaging. Gut 52(Suppl 4):iv12–iv16Google Scholar
  31. 31.
    Van Lanschot JJ, Hulscher JB, Buskens CJ, Tilanus HW, ten Kate FJ, Obertop H (2001) Hospital volume and hospital mortality for esophagectomy. Cancer 91:1574–1578Google Scholar
  32. 32.
    Van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H (1998) Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut 43:216–222Google Scholar
  33. 33.
    Wijnhoven BP, Tilanus HW, Dinjens WN (2001) Molecular biology of Barrett’s adenocarcinoma. Ann Surg 233:322–337Google Scholar
  34. 34.
    Zaninotto G, Parenti AR, Ruol A, Costantini M, Merigliano S, Ancona E (2000) Oesophageal resection for high-grade dysplasia in Barrett’s oesophagus. Br J Surg 87:1102–1105Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Marinke Westerterp
    • 1
  • Linetta B. Koppert
    • 2
  • Christianne J. Buskens
    • 1
  • Hugo W. Tilanus
    • 2
  • Fiebo J. W. ten Kate
    • 3
  • Jacques J. H. G. M. Bergman
    • 4
  • Peter D. Siersema
    • 5
  • Herman van Dekken
    • 6
  • Jan J. B. van Lanschot
    • 1
  1. 1.Department of SurgeryAcademic Medical Center at the University of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of SurgeryErasmus University Medical CenterRotterdamThe Netherlands
  3. 3.Department of PathologyAcademic Medical Center at the University of AmsterdamAmsterdamThe Netherlands
  4. 4.Department of GastroenterologyAcademic Medical Center at the University of AmsterdamAmsterdamThe Netherlands
  5. 5.Department of Gastroenterology and HepatologyErasmus University Medical CenterRotterdamThe Netherlands
  6. 6.Department of Pathology, Josephine Nefkens InstituteErasmus University Medical CenterRotterdamThe Netherlands

Personalised recommendations